Last $4.45 USD
Change Today -0.05 / -1.11%
Volume 5.8K
TBIO On Other Exchanges
Symbol
Exchange
Munich
OTC US
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

transgenomic inc (TBIO) Snapshot

Open
$4.45
Previous Close
$4.50
Day High
$4.45
Day Low
$4.40
52 Week High
10/23/13 - $7.44
52 Week Low
04/22/13 - $3.62
Market Cap
32.7M
Average Volume 10 Days
9.4K
EPS TTM
$-2.16
Shares Outstanding
7.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRANSGENOMIC INC (TBIO)

Related News

No related news articles were found.

transgenomic inc (TBIO) Related Businessweek News

No Related Businessweek News Found

transgenomic inc (TBIO) Details

Transgenomic, Inc. operates as a biotechnology company that focuses advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States, Italy, the United Kingdom, Germany, France, and internationally. It operates in two segments, Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. This segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies. It employs various genomic testing service technologies, including ICE COLD-PCR technology, a proprietary platform technology that enables detection of multiple unknown mutations from virtually any sample type, including tissue biopsies, blood, cell-free DNA, and circulating tumor cells. The Genetic Assays and Platforms segment offers the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also distributes bio-instruments produced by other manufacturers, as well as develops, manufactures, and sells consumable products that are used on multiple, independent platforms, including SURVEYOR Nuclease and a range of chromatography columns. The company sells its products through direct sales, support staff, dealers, and distributors to academic and medical institutions; and pharmaceutical, biotech, and commercial companies. Transgenomic, Inc. has a strategic collaboration agreement with PDI, Inc. The company was founded in 1997 and is headquartered in Omaha, Nebraska.

165 Employees
Last Reported Date: 03/27/14
Founded in 1997

transgenomic inc (TBIO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $96.1K
Compensation as of Fiscal Year 2012.

transgenomic inc (TBIO) Key Developments

Transgenomic Announces Collaboration with Raptor Pharmaceuticals for Genetic Testing Services

Transgenomic Inc. announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders. Leigh syndrome is a severe neurological disorder that typically arises in the first year of life. This condition is characterized by progressive loss of mental and movement abilities (psychomotor regression) and typically results in death within a few years, usually due to respiratory failure.

Dr. Michael A. Luther Joins Transgenomic, Inc.'s Board of Directors and Audit Committee

Transgenomic Inc. announced the appointment of Michael A. Luther, Ph.D., to its Board of Directors. Dr. Luther will also become a member of the Board's audit committee. He currently serves as Senior Vice President of Discovery and Development at Albany Molecular Research Inc.

Transgenomic Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Transgenomic Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. Net sales for the fourth quarter of 2013 were $6.2 million compared with $7.3 million for the same period in 2012. The decline in 2013 is mainly attributable to decreased volume in the Laboratory Services segment, principally in the Neurology business, and an unfavorable shift in mix, as a surplus of higher-priced tests were reported in last year's fourth quarter following a production disruption. This decline was partially offset by a significant increase in the Genetic Assays and Platforms segment, which resulted from an increase in unit sales of instruments in the U.S. and in Europe. The net loss available to common stockholders was $4.163 million, or $0.05 per diluted share, compared with a net loss of $2.478 million, or $0.03 per diluted share, for the fourth quarter of 2012. The majority of the increase in net loss was due to the change in non-cash warrant revaluation. Modified EBITDA, which is a non-GAAP measure that Transgenomic views as an appropriate and sound measure of the Company's results, was a loss of $2.6 million for the fourth quarter of 2013, compared to a $2.4 million loss for the same period for 2012. Loss from operations was $3.611 million compared to $3.267 million for the same period a year ago. Loss before income taxes was $4.087 million compared to $2.254 million for the same period a year ago. Net sales for the twelve months ended December 31, 2013 were $27.5 million, compared with $31.5 million in 2012. The decrease from 2012 was driven by reduced revenues in the Laboratory Services segment reflecting lower test volumes, as described in the fourth quarter commentary, partially offset by higher contract revenue associated with a collaboration agreement. The net loss available to common stockholders was $16.713 million, or $0.19 per diluted share, compared with a net loss of $8.987 million, or $0.13 per share, during the comparable period of 2012. Loss from operations was $15.759 million compared to $9.504 million for the same period a year ago. Loss before income taxes was $16.041 million compared to $8.181 million for the same period a year ago. Modified EBITDA was $12.433 million compared to $6.485 million for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBIO:US $4.45 USD -0.05

TBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Laboratory Corp of America Holdings $101.31 USD -0.64
QIAGEN NV €14.80 EUR -0.043
Quest Diagnostics Inc $59.48 USD -0.50
Roche Holding AG SFr.254.90 CHF +0.70
Sequenom Inc $2.59 USD 0.00
View Industry Companies
 

Industry Analysis

TBIO

Industry Average

Valuation TBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.2x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENOMIC INC, please visit www.transgenomic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.